DM.V. Article from the 18 th Datametrex AI Ltd represents an unusual situation for a junior company. The company has been recording record revenues and earnings during the past year, much of that coming from sales of Covid-19 testing kits. Despite the massive global vaccination efforts to date, new variants are emerging as the virus mutates, therefore the need for Covid testing will likely continue for the next several years, which should continue to benefit Datametrex’s revenues and profitability.
The revenues from the cybersecurity division continue to gain traction and its importance in the fight against social media disinformation efforts will only become greater. Telemedicine received a major boost in credibility and public acceptance due to the pandemic, and it is expected to become a normal, widely accepted methodology for patients to connect with their primary medical care providers.
With 352.8 million shares outstanding and a relatively modest market capitalization of $70.6 million, and strong revenue and earnings growth, Datametrex AI represents a somewhat de-risked growth company. The management team has extensive experience in artificial intelligence, medicine, cybersecurity, big data analytics, medical diagnostics and have held senior executive positions in both public and private companies.
The firm has a strong, debt-free balance sheet and a solid cash position. If historical reporting dates apply, shareholders can likely expect the company’s Q2 financials to be released sometime over the 4-6 weeks. It would not be too surprising, if revenue and profit growth continues to accelerate, that the Company considers a move to a more senior stock exchange at some point, which could bring more institutional interest to the name.